QUIET JANUARY: BDI-40 FALLS 1.1%, ASX200 UP 5.1%
February 14th 2012 02:23
Biotech Daily
Wednesday February 1, 2012
Daily news on ASX-listed biotechnology companies
QUIET JANUARY: BDI-40 FALLS 1.1%, ASX200 UP 5.1%
CLINUVEL, GENETIC TECH UP MORE THAN 30%
BIONOMICS DOWN 20%
CLINUVEL, GENETIC TECH UP MORE THAN 30%
BIONOMICS DOWN 20%
Wednesday February 1, 2012
Daily news on ASX-listed biotechnology companies
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIOTECH DAILY’S TOP 40 INDEX
The Summer holidays were a generally quiet time for the biotechnology sector with modest rises dragged down by a few significant, but low percentage, falls.
Acrux was up 19.0 percent adding $91 million to the Biotech Daily Top 20 and Top 40 Indices (BDI-20, BDI-40), but six percent falls by Mesoblast and Heartware removed $167 million. Nineteen of the BDI-40 companies were up, 18 fell and three were unchanged.
The BDI-40 (which does not include the Big Caps of Cochlear, CSL and Resmed) fell 1.1 percent in January 2012, while the S&P ASX200 climbed 5.1 percent. For the year to January 31, 2012, the BDI-40 fell 9.3 percent compared to the ASX200 falling 10.3 percent – the first time in several years that the BDI-40 has fallen in line with the benchmark index (see chart below).
The collective value of the three Big Caps lost 19.3 percent over the 12 months to January 31, 2012, with CSL more than $1 billion above its August 31, 2011 low of $14.8 billion but more than $4 billion (20.2%) below its $20.3 billion market capitalization at January 31, 2011. Resmed was up 10.9 percent for the month to $4.3 billion while Cochlear fell 5.6 percent to $3.4 billion.
Clinuvel was January’s best, up 35.4 percent to a market capitalization of $65 million, as it closes in on Scenesse registration, followed by Genetic Technologies up 31.25 percent to $63 million, Uscom up 33.3 percent on thin volumes to $4 million and Patrys recovering 30 percent from its placement to $13 million. Benitec was up 28.6 percent, followed by Acrux (19.0%), Viralytics (16%), Sunshine Heart (11.6%) and Bioniche (10.8%).
Bionomics led the falls, down $41 million or 20.2 percent to $162, coinciding with the Ironwood licence for anti-anxiety compound BNC210, when many observers were expecting a bigger deal with greater value clarity (BD: Jan 22, 2012). Cathrx slipped a further 28.6 percent to $18 million while awaiting a European deal for its catheters, followed by Allied Health and Psivida, both down 15.4 percent, Cellmid (14.3%), Compumedics (13.3%), and Reva (11.1%).
BDI-40 v ASX200 Jun 30, 2006 To Jan 31, 2012
BDI-40 v ASX200 Jan 31, 2011 To Jan 31, 2012
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 6 |
| Vote |
Add To: 
subscribe to this blog